Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Pharmacies have been given instructions by the General Pharmaceutical Council on new steps they must follow before ...

Novo Nordisk reported soaring sales for weight loss drug Wegovy (James Manning/PA) Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo ...

The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, were key to its earnings beat. Combined, they brought in $24.9 billion for the year. That's compared ...

The company is spending billions to ramp up its Wegovy output as demand soars. "Emissions come with growth," said Katrine DiBona, corporate vice president of global public affairs and ...

Denmark is home to Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024 but its manufacturer has predicted growth will slow this year. Novo Nordisk's rise to become one of Europe's ...

A breakthrough in weight loss medication is on the horizon. While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient ...